Cargando…

Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, and antiangiogenic/immunomodulatory agents. This review paper intends to put together and discuss the spectrum of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Argyriou, Andreas A, Kyritsis, Athanasios P, Makatsoris, Thomas, Kalofonos, Haralabos P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964029/
https://www.ncbi.nlm.nih.gov/pubmed/24672257
http://dx.doi.org/10.2147/CMAR.S44261
_version_ 1782308590641479680
author Argyriou, Andreas A
Kyritsis, Athanasios P
Makatsoris, Thomas
Kalofonos, Haralabos P
author_facet Argyriou, Andreas A
Kyritsis, Athanasios P
Makatsoris, Thomas
Kalofonos, Haralabos P
author_sort Argyriou, Andreas A
collection PubMed
description Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, and antiangiogenic/immunomodulatory agents. This review paper intends to put together and discuss the spectrum of chemotherapy-induced peripheral neuropathy (CIPN) characteristics so as to highlight areas of future research to pursue on the topic. Current knowledge shows that the pathogenesis of CIPN still remains elusive, mostly because there are several sites of involvement in the peripheral nervous system. In any case, it is acknowledged that the dorsal root ganglia of the primary sensory neurons are the most common neural targets of CIPN. Both the incidence and severity of CIPN are clinically under- and misreported, and it has been demonstrated that scoring CIPN with common toxicity scales is associated with significant inter-observer variability. Only a proportion of chemotherapy-treated patients develop treatment-emergent and persistent CIPN, and to date it has been impossible to predict high-and low-risk subjects even within groups who receive the same drug regimen. This issue has recently been investigated in the context of pharmacogenetic analyses, but these studies have not implemented a proper methodological approach and their results are inconsistent and not really clinically relevant. As such, a stringent approach has to be implemented to validate that information. Another open issue is that, at present, there is insufficient evidence to support the use of any of the already tested chemoprotective agents to prevent or limit CIPN. The results of comprehensive interventions, including clinical, neurophysiological, and pharmacogenetic approaches, are expected to produce a consistent advantage for both doctors and patients and thus allow the registration and analysis of reliable data on the true characteristics of CIPN, eventually leading to potential preventive and therapeutic interventions.
format Online
Article
Text
id pubmed-3964029
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39640292014-03-26 Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature Argyriou, Andreas A Kyritsis, Athanasios P Makatsoris, Thomas Kalofonos, Haralabos P Cancer Manag Res Review Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, and antiangiogenic/immunomodulatory agents. This review paper intends to put together and discuss the spectrum of chemotherapy-induced peripheral neuropathy (CIPN) characteristics so as to highlight areas of future research to pursue on the topic. Current knowledge shows that the pathogenesis of CIPN still remains elusive, mostly because there are several sites of involvement in the peripheral nervous system. In any case, it is acknowledged that the dorsal root ganglia of the primary sensory neurons are the most common neural targets of CIPN. Both the incidence and severity of CIPN are clinically under- and misreported, and it has been demonstrated that scoring CIPN with common toxicity scales is associated with significant inter-observer variability. Only a proportion of chemotherapy-treated patients develop treatment-emergent and persistent CIPN, and to date it has been impossible to predict high-and low-risk subjects even within groups who receive the same drug regimen. This issue has recently been investigated in the context of pharmacogenetic analyses, but these studies have not implemented a proper methodological approach and their results are inconsistent and not really clinically relevant. As such, a stringent approach has to be implemented to validate that information. Another open issue is that, at present, there is insufficient evidence to support the use of any of the already tested chemoprotective agents to prevent or limit CIPN. The results of comprehensive interventions, including clinical, neurophysiological, and pharmacogenetic approaches, are expected to produce a consistent advantage for both doctors and patients and thus allow the registration and analysis of reliable data on the true characteristics of CIPN, eventually leading to potential preventive and therapeutic interventions. Dove Medical Press 2014-03-19 /pmc/articles/PMC3964029/ /pubmed/24672257 http://dx.doi.org/10.2147/CMAR.S44261 Text en © 2014 Argyriou et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Argyriou, Andreas A
Kyritsis, Athanasios P
Makatsoris, Thomas
Kalofonos, Haralabos P
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
title Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
title_full Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
title_fullStr Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
title_full_unstemmed Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
title_short Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
title_sort chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964029/
https://www.ncbi.nlm.nih.gov/pubmed/24672257
http://dx.doi.org/10.2147/CMAR.S44261
work_keys_str_mv AT argyriouandreasa chemotherapyinducedperipheralneuropathyinadultsacomprehensiveupdateoftheliterature
AT kyritsisathanasiosp chemotherapyinducedperipheralneuropathyinadultsacomprehensiveupdateoftheliterature
AT makatsoristhomas chemotherapyinducedperipheralneuropathyinadultsacomprehensiveupdateoftheliterature
AT kalofonosharalabosp chemotherapyinducedperipheralneuropathyinadultsacomprehensiveupdateoftheliterature